Wednesday, November 6, 2013
• Cel-Sci Corp., of Vienna, Va., said a second interim review of the safety data from its open-label, randomized, Phase III study of immunotherapy candidate Multikine (leukocyte interleukin, injection) was conducted, with the independent data monitoring board recommending that the study continue unmodified.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.